Comparative Pharmacology
Head-to-head clinical analysis: EPIPEN versus SYMJEPI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPIPEN versus SYMJEPI.
EPIPEN vs SYMJEPI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective alpha-1, alpha-2, beta-1, beta-2, beta-3 adrenergic receptor agonist; causes vasoconstriction (alpha-1), bronchodilation (beta-2), and increased cardiac contractility and heart rate (beta-1).
Symjepi (epinephrine) is a direct-acting sympathomimetic amine that acts on alpha- and beta-adrenergic receptors. Alpha-adrenergic receptor activation leads to vasoconstriction, increased peripheral vascular resistance, and decreased mucosal edema. Beta-adrenergic receptor activation results in bronchodilation, positive inotropic and chronotropic cardiac effects, and relaxation of gastrointestinal smooth muscle.
0.3 mg intramuscularly (lateral thigh) every 5-15 minutes as needed for anaphylaxis.
0.3 mg intramuscular (IM) or subcutaneous (SC) injection into anterolateral aspect of thigh, repeat every 5-15 minutes as needed for anaphylaxis.
None Documented
None Documented
2-3 minutes (IV); clinical context: ultra-short half-life necessitates repeated doses or continuous infusion for sustained effect
The terminal elimination half-life of epinephrine is approximately 2-3 minutes when administered intravenously. This short half-life reflects rapid metabolic clearance and necessitates continuous infusion for sustained effect. After intramuscular injection, absorption is slower, but elimination half-life remains brief (about 2-5 minutes for the beta phase). The clinical context: Due to rapid clearance, the drug's effects wane quickly after discontinuation.
Renal (90% as metabolites, 10% unchanged); biliary/fecal (<5%)
Epinephrine is rapidly metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Metabolites, primarily metanephrine and vanillylmandelic acid (VMA), are excreted in urine. Less than 5% of administered dose is excreted unchanged in urine. Biliary/fecal elimination is negligible.
Category C
Category C
Adrenergic Agonist
Adrenergic Agonist